Literature DB >> 22796230

GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes.

Micah J Hill1, Rebecca J Chason, Mark D Payson, James H Segars, John M Csokmay.   

Abstract

Gonadotrophin-releasing hormone (GnRH) antagonist rescue is performed by replacing a GnRH agonist with a GnRH antagonist in patients with rapidly rising serum oestradiol who are at risk of ovarian hyperstimulation syndrome (OHSS) during stimulation. It results in a rapid reduction in serum oestradiol, allowing for the avoidance of cycle cancellation and the continuation of exogenous gonadotrophin administration. A total of 387 patients who underwent GnRH antagonist rescue for ovarian hyperresponse were compared with 271 patients who did not receive GnRH antagonist rescue and had oestradiol concentrations >4000 pg/ml on the day of human chorionic gonadotrophin (HCG) administration. GnRH antagonist rescue decreased the mean oestradiol concentration by 35% on the first day of use. There was no difference in oocyte maturity (82% versus 83%) or fertilization rate (69% versus 67%) between the antagonist rescue and comparison groups, respectively. The percentage of high-grade embryos on day 3 and the blastocyst development rate were also similar between groups. The live-birth rate was 41.9% in the antagonist rescue group and 36.9% in the comparison group. GnRH antagonist rescue enabled cycle completion with high live-birth rates in patients at risk for OHSS. GnRH antagonist was associated with high oocyte quality, blastocyst development and pregnancy. Gonadotrophin-releasing hormone (GnRH) antagonist rescue is a protocol to reduce the risk of ovarian hyperstimulation syndrome (OHSS) in assisted reproduction treatment. Patients who have a hyperresponse to medication during their treatment cycle have their GnRH agonist discontinued and a GnRH antagonist started in its place. This causes a rapid reduction in oestrogen concentrations and allows for the continuation of stimulation medication. We evaluated the effectiveness of this protocol by comparing patients who had GnRH antagonist rescue against high-responding patients who did not receive GnRH antagonist rescue. GnRH antagonist rescue resulted in a 35% reduction in oestrogen concentration and only a 1.5% cycle cancellation rate. There were no differences in oocyte maturity or fertilization between the two groups. There were no differences in the quality of day-3 and day-5 embryos between the two groups. The live birth rate was 41.9% in the antagonist rescue group and 36.9% in the comparison group. GnRH antagonist rescue reduced serum oestradiol concentrations and enabled cycle completion with high live-birth rates in patients at risk for OHSS. GnRH antagonist was associated with high oocyte quality, blastocyst development and pregnancy. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796230      PMCID: PMC3434231          DOI: 10.1016/j.rbmo.2012.05.004

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  16 in total

1.  Oocyte and embryo quality after coasting: the experience from oocyte donation.

Authors:  V Isaza; J A García-Velasco; M Aragonés; J Remohí; C Simón; A Pellicer
Journal:  Hum Reprod       Date:  2002-07       Impact factor: 6.918

Review 2.  Ovarian hyperstimulation syndrome: an update review.

Authors:  A Golan; R Ron-el; A Herman; Y Soffer; Z Weinraub; E Caspi
Journal:  Obstet Gynecol Surv       Date:  1989-06       Impact factor: 2.347

3.  Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome.

Authors:  Robert L Gustofson; Frederick W Larsen; Mark R Bush; James H Segars
Journal:  Fertil Steril       Date:  2006-01       Impact factor: 7.329

4.  Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome.

Authors:  Ragaa Mansour; Mohamed Aboulghar; Gamal Serour; Yehia Amin; Ahmed M Abou-Setta
Journal:  Hum Reprod       Date:  2005-07-08       Impact factor: 6.918

5.  Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.

Authors:  Robert L Gustofson; James H Segars; Frederick W Larsen
Journal:  Hum Reprod       Date:  2006-09-11       Impact factor: 6.918

6.  Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.

Authors:  A Enskog; M Henriksson; M Unander; L Nilsson; M Brännström
Journal:  Fertil Steril       Date:  1999-05       Impact factor: 7.329

Review 7.  The ovarian hyperstimulation syndrome.

Authors:  J G Whelan; N F Vlahos
Journal:  Fertil Steril       Date:  2000-05       Impact factor: 7.329

Review 8.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

Review 9.  Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.

Authors:  Annick Delvigne; Serge Rozenberg
Journal:  Hum Reprod Update       Date:  2002 Nov-Dec       Impact factor: 15.610

10.  The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features.

Authors:  A Delvigne; A Demoulin; J Smitz; J Donnez; P Koninckx; M Dhont; Y Englert; L Delbeke; L Darcis; S Gordts
Journal:  Hum Reprod       Date:  1993-09       Impact factor: 6.918

View more
  9 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  Embryo transfer simulation improves pregnancy rates and decreases time to proficiency in Reproductive Endocrinology and Infertility fellow embryo transfers.

Authors:  Ryan J Heitmann; Micah J Hill; John M Csokmay; Justin Pilgrim; Alan H DeCherney; Shad Deering
Journal:  Fertil Steril       Date:  2017-03-11       Impact factor: 7.329

3.  Live births achieved via IVF are increased by improvements in air quality and laboratory environment.

Authors:  Ryan J Heitmann; Micah J Hill; Aidita N James; Tim Schimmel; James H Segars; John M Csokmay; Jacques Cohen; Mark D Payson
Journal:  Reprod Biomed Online       Date:  2015-05-08       Impact factor: 3.828

4.  Serum human chorionic gonadotropin levels on the day before oocyte retrieval do not correlate with oocyte maturity.

Authors:  Gary Levy; Micah J Hill; Christina Ramirez; Torrie Plowden; Justin Pilgrim; Robin S Howard; James H Segars; John Csokmay
Journal:  Fertil Steril       Date:  2013-01-30       Impact factor: 7.329

5.  The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome.

Authors:  Junwei Qu; Yena Che; Pei Xu; Yanjie Xia; Xiaoke Wu; Yong Wang
Journal:  Int J Fertil Steril       Date:  2015-02-07

6.  Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study.

Authors:  Ya-Qin Wang; Nan Yu; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jing Yang
Journal:  Exp Ther Med       Date:  2014-10-06       Impact factor: 2.447

Review 7.  The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome.

Authors:  Neil Chappell; William E Gibbons
Journal:  Clin Exp Reprod Med       Date:  2017-06-30

8.  Successful pregnancy and live birth from a hypogonadotropic hypogonadism woman with low serum estradiol concentrations despite numerous oocyte maturations: a case report.

Authors:  Kaori Matsumoto; Kazuhiko Imakawa; Chuyu Hayashi
Journal:  BMC Pregnancy Childbirth       Date:  2017-09-20       Impact factor: 3.007

9.  GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.

Authors:  Usama M Fouda; Ahmed M Sayed; Hesham S Elshaer; Bahaa Eldin M Hammad; Mona M Shaban; Khaled A Elsetohy; Mohamed A Youssef
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.